Swiss - Delayed Quote CHF
Novartis AG (NOVNEE.SW)
91.14
-1.42
(-1.53%)
As of 9:41:28 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
53.22B
51.72B
46.66B
43.46B
43.97B
Cost of Revenue
12.96B
12.83B
12.47B
11.58B
11.73B
Gross Profit
40.26B
38.90B
34.19B
31.88B
32.24B
Operating Expense
24.43B
24.35B
24.42B
23.93B
22.18B
Operating Income
15.83B
14.54B
9.77B
7.95B
10.06B
Net Non Operating Interest Income Expense
-724.00M
-686.00M
-419.00M
-574.00M
-794.00M
Other Income Expense
-192.00M
-218.00M
-227.00M
-195.00M
15.27B
Pretax Income
14.92B
13.64B
9.12B
7.18B
24.53B
Tax Provision
2.06B
1.70B
551.00M
1.13B
1.62B
Net Income Common Stockholders
12.86B
11.94B
14.85B
6.96B
24.02B
Diluted NI Available to Com Stockholders
12.86B
11.94B
14.85B
6.96B
24.02B
Basic EPS
6.44
5.92
7.15
3.19
10.71
Diluted EPS
6.38
5.87
7.10
3.17
10.63
Basic Average Shares
2.00B
2.02B
2.08B
2.18B
2.24B
Diluted Average Shares
2.02B
2.04B
2.09B
2.20B
2.26B
Total Operating Income as Reported
15.83B
14.54B
9.77B
7.95B
10.06B
Total Expenses
37.39B
37.18B
36.89B
35.52B
33.92B
Net Income from Continuing & Discontinued Operation
12.86B
11.94B
14.85B
6.96B
24.02B
Normalized Income
13.01B
12.10B
8.77B
6.20B
22.97B
Interest Income
--
568.00M
627.00M
377.00M
70.00M
Interest Expense
1.05B
1.01B
855.00M
800.00M
787.00M
Net Interest Income
-724.00M
-686.00M
-419.00M
-574.00M
-794.00M
EBIT
15.97B
14.65B
9.98B
7.98B
25.32B
EBITDA
21.88B
20.71B
18.25B
14.68B
30.91B
Reconciled Cost of Revenue
12.96B
12.83B
12.47B
11.58B
11.73B
Reconciled Depreciation
5.91B
6.07B
8.28B
6.71B
5.60B
Net Income from Continuing Operation Net Minority Interest
12.86B
11.94B
8.57B
6.05B
22.91B
Total Unusual Items Excluding Goodwill
-180.00M
-180.00M
-214.00M
-184.00M
-69.00M
Total Unusual Items
-180.00M
-180.00M
-214.00M
-184.00M
-69.00M
Normalized EBITDA
22.06B
20.89B
18.47B
14.87B
30.98B
Tax Rate for Calcs
0.14
0.12
0.06
0.16
0.08
Tax Effect of Unusual Items
-24.83M
-22.50M
-12.84M
-28.89M
-5.59M
12/31/2021 - 11/25/2013
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
JNJd.XC
RHO.HM Roche Holding AG
311.80
0.00%
AMG.F Amgen Inc.
239.95
+0.57%
ABBV.NE AbbVie Inc.
26.86
-4.24%
0QIU.IL Novo Nordisk A/S
462.15
+3.05%
H02.SI Haw Par Corporation Limited
11.51
-0.86%
ROG.SW Roche Holding AG
265.70
-2.10%
NOV.DE Novo Nordisk A/S
61.88
+4.93%
AZN.L AstraZeneca PLC
10,440.95
-2.42%
BIIB Biogen Inc.
116.82
-4.09%